Drug Information

Drug General Information
Drug ID
D0U2DH
Former ID
DNC003569
Drug Name
CC-1088
Drug Type
Small molecular drug
Indication Crohn's disease [ICD9: 555; ICD10:K50] Phase 2 [521533]
Structure
Download
2D MOL

3D MOL
Formula
C23H24N2O5
Canonical SMILES
COC1=C(C=C(C=C1)C(CC(=O)N)N2C(=O)C3=CC=CC=C3C2=O)OC4CCC<br />C4
InChI
1S/C23H24N2O5/c1-29-19-11-10-14(12-20(19)30-15-6-2-3-7-15)18(13-21(24)26)25-22(27)16-8-4-5-9-17(16)23(25)28/h4-5,8-12,15,18H,2-3,6-7,13H2,1H3,(H2,24,26)
InChIKey
DDYUBCCTNHWSQM-UHFFFAOYSA-N
PubChem Compound ID
9844338
Target and Pathway
Target(s) CAMP-specific 3',5'-cyclic phosphodiesterase 4B Target Info Inhibitor [534801]
Type IV phosphodiesterase Target Info Inhibitor [534801]
CAMP-specific 3',5'-cyclic phosphodiesterase 4A Target Info Inhibitor [534801]
KEGG Pathway Purine metabolism
cAMP signaling pathway
Morphine addictionhsa00230:Purine metabolism
Morphine addiction
NetPath Pathway IL5 Signaling Pathway
IL2 Signaling Pathway
PathWhiz Pathway Purine Metabolism
Reactome DARPP-32 events
G alpha (s) signalling eventsR-HSA-180024:DARPP-32 events
G alpha (s) signalling events
WikiPathways G Protein Signaling Pathways
Myometrial Relaxation and Contraction Pathways
Nuclear Receptors Meta-Pathway
Opioid SignallingWP35:G Protein Signaling Pathways
TSH signaling pathwayWP35:G Protein Signaling Pathways
References
Ref 521533ClinicalTrials.gov (NCT00045786) Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes. U.S. National Institutes of Health.
Ref 534801Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669-74.Thalidomide analogs and PDE4 inhibition.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.